The latest news:

• Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.        Impressive gain in progression free survival. These trials should NOT even try to report on overall survival. They say 83% of patients in the control group took Avastin at the time of recurrence.  So they are comparing patients who took Avastin to patients who took Avastin and found no difference in overall survival. Duh.  
  



• Ependymoma Awareness Day         From our good friends at the CERN Foundation
  



• Tocagen to Present at Three Oncology Conferences         It is impressive that so many of the brain tumor foundation (including the Musella Foundation:) have come together to support this promising research.
  

BrainTumor Co-Payment Assistance Program Status:

• CLOSED to new applicants